HIV InfectionsSUSTAINNCT05040841
Supporting Sustained HIV Treatment Adherence After Initiation
A study testing M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses in people with HIV Infections and Adherence, Medication, run by Boston University at 3 sites in South Africa.
Trial summary
The investigators will implement a 24-month fractional factorial design study (Aim 1). The investigators will recruit 510 patients initiating antiretroviral therapy (ART) at three City of Cape Town ART clinics. Each patient will have adherence monitored using the Wisepill® electronic adherence monitoring device (EAM). Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- HIV Infections, Adherence, Medication
- What is being tested?
- M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 534 participants
- Where
- 3 sitesSouth Africa
- Study dates
- 9 Mar 2022to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Adults (≥18 years) and adolescents 16-17 years.
- HIV-positive and attending a local City of Cape Town (COCT) clinic to commence ART.
- Able to provide full informed consent, with a written signature. For those who are illiterate, a witness will be present throughout the process and will sign the form, while the participant will add their right thumb print. For those who are aged 16-17 years, informed written assent will be obtained, and the adolescent must have a parent or guardian who can provide full informed consent (see **below for how parent/guardian is defined for this purpose).
- Access to a working cellphone and willingness to receive study-related messaging on that phone.
- Willingness to comply with study procedures, including providing regular updates of contact details /locator information, and use a EAM device for the duration of participation.
- Other Inclusion Criteria:
Show all 15Show fewer
- Aim 1: In-depth interviews (IDIs) with subset of trial subjects at baseline and months 12 and 24.
- Participation in the main trial.
- Self-reported prior experience with substance use, depression, gender inequity, stigma, or transport/clinic issues.
- Aim 2: Questionnaires and IDIs with staff members at study clinics (three total clinics).
- Adults (≥18 years)
- Staff at study clinics, providing HIV care and/or treatment.
- Aim 2: Focus group discussion (FGD) with City of Cape Town officials.
- Adults (≥18 years)
- Staff at City of Cape Town.
Who cannot join
- Clinical conditions as assessed by the COCT clinic clinicians at first visit e.g. renal disease, which preclude the use of a single tablet regimen (with the exception of those on tuberculosis (TB) treatment who are required to take an extra dose of dolutegravir daily).
- Planning to leave Cape Town permanently within the next 24 months.
- Being perinatally infected with HIV. Being infected from birth typically means a set of experiences and complications at a young age that require unique and special attention.
- If an adolescent, taking their ART medication as a syrup, as they are required to use the electronic adherence monitor (Wisepill device), which is only suitable for tablets.
- Other Inclusion Criteria:
- Aim 1: IDIs with trial subjects.
Show all 10Show fewer
- None.
- Aim 2: Questionnaires and IDIs with staff members at clinics. • None.
- Aim 2: FGD with City of Cape Town officials.
- None.
Trial locations and contacts
3 sites in 1 country.
South Africa3 sites
Mzamomhle
Cape Town, Western Cape
Phumlani
Cape Town, Western Cape
Weltevreden Valley
Cape Town, Western Cape
About this study
The investigators will implement a 24-month fractional factorial design study (Aim 1). The investigators will recruit 510 patients initiating antiretroviral therapy (ART) at three City of Cape Town ART clinics. Each patient will have adherence monitored using the Wisepill® electronic adherence monitoring device (EAM). After eligibility has been confirmed, each participant will be randomized to one of 16 experimental conditions. Each condition includes a unique combination of five adherence intervention components. Three of these components focus on identifying individuals with poor adherence, with increasing degrees of sophistication, with immediate linkage to adherence support. Two components focus on supporting good adherence. They both supplement the existing adherence support program delivered at the study clinics operated by City of Cape Town (standard of care component). Based on Self-Determination Theory, the investigators postulate these intervention components will: 1) enhance feelings of autonomy support, social support, and knowledge; 2) improve motivation and self-competence; and 3) increase ART retention, adherence, and viral suppression. A subset of the participants, as well as clinic staff, will be invited to in-depth interviews to explore mediating factors (Aim 1) and the implementation process (Aim 2); and the data collected in Aims 1 and 2 will be used to explore cost effectiveness (Aim 3).
Read the detailed description
The study's primary research goal is to identify the optimal combination of evidence-based and scalable HIV interventions for low-resource, high-burden settings. The investigators propose to 1) test the relative contribution of five promising intervention components; 2) collect cost and other implementation data; and 3) create a multi-component intervention package to optimize cost-effectiveness and implementation success. Of the five components, three are methods of non-adherence detection plus patient outreach; two are adherence support methods that can be integrated into Cape Town healthcare systems. These will not overcome all challenges that ART patients experience (e.g., structural barriers such as food insecurity) but they represent scalable, feasible, acceptable, and effective options. Notably, they are all behavioral approaches grounded in the experience and priorities of local health officials with whom the investigators have worked to identify scaleable interventions. While the study will be in Cape Town, it is broadly adaptable to other resource-limited settings.
The gold standard for testing interventions is the randomized controlled trial (RCT), which minimizes bias when testing cause and effect of a new exposure. When testing an intervention with more than one element, however, untangling the effect of individual elements is impossible. Indeed, data on the performance of individual components and their interactions-critical for developing and refining the components of a packaged intervention-is lost in an RCT. Notably, clinical care typically relies on packages of services, not single interventions, and packaged interventions are recommended for ART support. An effective way to test a multi-component intervention is to use the novel Multiphase Optimization STrategy (MOST), an engineering-inspired method for identifying the most efficacious combination of components in a packaged intervention, thus allowing researchers to drop inactive or weakly-performing components and construct an optimized package based on effect, cost, and other features. Once the optimized multi-component intervention is chosen, an RCT or quasi-experiment can follow to determine whether the optimized package yields superior outcomes compared to existing standards. MOST encompasses three phases: 1) preparation; 2) optimization; and 3) evaluation, often in an RCT. In this project, we have completed preparation, including a pilot study in Cape Town. SUSTAIN will comprise the middle optimization phase. The evaluation phase will be the focus of a future study.
The specific aims are:
Aim 1. Employ a highly efficient fractional factorial design to determine the effects of five intervention components on the primary outcome (HIV viral suppression) and secondary outcomes (ART adherence measured by EAM, ART retention per clinic records, days of unsuppressed virus, time to nonadherence detection, and time to linkage to support). The investigators will explore effect mechanisms quantitatively and qualitatively.
Aim 2. Evaluate the intervention components to address implementation, service, and client outcomes according to the Proctor framework. Data collection will involve tracking of intervention component use, time and motion studies, and quantitative surveys and qualitative interviews with participants and staff.
Aim 3. Use the effectiveness data collected in Aim 1 and the implementation and client outcomes in Aim 2 to model the multi-component intervention optimized for cost-effectiveness and implementation success.
Study Summary This study is designed to advance the translation of evidence-based interventions into clinical settings to benefit patients. There is ample evidence on what works to support ART adherence and retention-much of it from our own research. The investigators partnered with local officials and clinical staff in Cape Town to review the evidence and to conduct formative research to identify the most effective, acceptable, and feasible intervention options for patients and providers. The proposed study represents the next critical step: the investigators will test the intervention components that emerged from the formative work, encompassing elements to both rapidly identify nonadherent patients and to strengthen the support they receive once identified, to provide the data needed to construct the most cost-effective and sustainable multi-component intervention. The choice of intervention components will allow a critical test of advanced monitoring technology compared to simpler tools to identify nonadherence. By using an innovative MOST design to guide collection and analysis of efficacy, cost, and other implementation data, the study aligns with NIH's goals of using novel scientific methods to advance implementation science.
- Conditions
- HIV Infections, Adherence, Medication
- Being tested
- M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill, M3/EAM: Immediate outreach to subject after EAM-identified missed doses, S1/Text: Weekly check-in texts, S2/Peer: Enhanced peer group support
- Keywords
- HIV treatment, HIV treatment adherence, Retention in care, Randomized controlled trial, Fractional factorial design, Proctor implementation science framework, Cost-effectiveness, South Africa, Community clinics
- Medical subject headings
- HIV Infections, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
M1/OTR: Immediate outreach to subject due to unsuppressed viral load test resultBehavioural
Also called M1/OTR
Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the "Risk of Treatment Failure" (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1.
M2/PRM: Immediate outreach to subject after a missed pharmacy refillBehavioural
Also called M2/PRM
The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
M3/EAM: Immediate outreach to subject after EAM-identified missed dosesBehavioural
Also called M3/EAM
The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
S1/Text: Weekly check-in textsBehavioural
Also called S1/Text
Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. "how are you?" with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.
S2/Peer: Enhanced peer group supportBehavioural
Also called S2/Peer
Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. "Enhanced" peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Condition 1 | Experimental | Includes 1 intervention:
S2/Peer: Enhanced peer group support. Receives: Behavioral: S2/Peer: Enhanced peer group support |
| Condition 2 | Experimental | Includes 1 intervention:
S1/Text: Weekly check-in text messages. Receives: Behavioral: S1/Text: Weekly check-in texts |
| Condition 3 | Experimental | Includes 1 intervention:
M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient. Receives: Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses |
| Condition 4 | Experimental | Includes 3 interventions:
M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. Receives: Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 5 | Experimental | Includes 1 intervention:
M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient. Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill |
| Condition 6 | Experimental | Includes 3 interventions:
M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 7 | Experimental | Includes 3 interventions:
M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support. Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 8 | Experimental | Includes 3 interventions:
M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages. Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts |
| Condition 9 | Experimental | Includes 1 intervention:
M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result |
| Condition 10 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 11 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 12 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts |
| Condition 13 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S2/Peer: Enhanced peer group support |
| Condition 14 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S1/Text: Weekly check-in texts |
| Condition 15 | Experimental | Includes 3 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses |
| Condition 16 | Experimental | Includes 5 interventions:
M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support |
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV viral suppression at 24 months
This outcome will measure the effect of the interventions on HIV viral suppression from enrollment to the end of study participation. HIV viral suppression will be defined as % plasma viral load (VL) <50 copies/mL (dichotomous).
Measured: 24 months
Secondary outcomes (6)
HIV viral suppression at 12 months
This outcome will be an intermediary outcome measure performed half-way through study participation. HIV viral suppression will be defined as % plasma VL <50 copies/mL (dichotomous).
Measured: 12 months
Change in HIV viral load between baseline and 12 months
This will measure the effect on HIV viral load of exposure to interventions during the first half of study participation. It will be measured as the change in HIV viral load, defined as the mean change in HIV plasma between month 0 and month 12 post-enrollment (continuous).
Measured: baseline, 12 months
Change in HIV viral load between baseline and 24 months
This will measure the effect on HIV viral load of exposure to interventions over the entire course of study participation. It will be measured as the change in HIV viral load, defined as the mean change in HIV plasma between month 0 and month 24 post-enrollment (continuous).
Measured: baseline, 24 months
Days of unsuppressed virus between baseline and 24 months
This measure will determine the days that subjects experience unsuppressed virus, measured between baseline and the end of the study at 24 months (continuous).
Measured: baseline, 24 months
Achievement of ≥ 90% adherence in month 24
This measure indicates whether subject achieved adherence of 90% or more during the final month of study participation in month 24 (dichotomous).
Measured: month 24
Mean adherence from baseline through 24 months
This measure indicates mean adherence over the entire length of the study from enrollment through 24 months (continuous).
Measured: baseline through 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2021
- Study start9 Mar 2022
- Primary completion28 May 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- More trials run by Boston UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- The investigators will randomize subjects to one of 16 conditions, using a fractional factorial design to determine the effects of five intervention components.
- Masking
- None (open label)
- Enrolment
- 534 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston University
- Sponsor type
- University, hospital or other
- Collaborators
- Desmond Tutu HIV Foundation, Massachusetts General Hospital, New York University, National Institute of Mental Health (NIMH)
- Responsible party
- Sponsor
- Investigators
- Lora Sabin, PhD, MA, Principal investigator, Boston University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05040841
- Sponsor's protocol ID
- H-41920
- Other IDs
- 1R01MH125703-01A1
- Acronym
- SUSTAIN
- Status last verified
- Jul 2026
- First submitted
- 1 Sep 2021
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We have not yet made a detailed plan, but tentatively, we will deposit de-identified IPD in a repository at Boston University (BU) School of Public Health and the Desmond Tutu Health Foundation that can be made available to other researchers once our planned analyses are complete.
Publications
Jennings L, West RL, Halim N, Kaiser JL, Gwadz M, MacLeod WB, Gifford AL, Haberer JE, Orrell C, Sabin LL. Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design. Trials. 2023 May 5;24(1):310. doi: 10.1186/s13063-023-07322-z.
PubMed 37147725
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supporting Sustained HIV Treatment Adherence After Initiation
- ClinicalTrials.gov ID
- NCT05040841
- Acronym / sponsor ID
- SUSTAIN / H-41920
- Conditions
- HIV Infections, Adherence, Medication
- Keywords
- HIV treatment, HIV treatment adherence, Retention in care, Randomized controlled trial, Fractional factorial design, Proctor implementation science framework, Cost-effectiveness, South Africa
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 534 participants (actual)
- Lead sponsor
- Boston UniversityUniversity, hospital or other
- Collaborators
- Desmond Tutu HIV Foundation, Massachusetts General Hospital, New York University, National Institute of Mental Health (NIMH)
- Study start
- 9 Mar 2022 (actual)
- Primary completion
- 28 May 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 10 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will implement a 24-month fractional factorial design study (Aim 1). The investigators will recruit 510 patients initiating antiretroviral therapy (ART) at three City of Cape Town ART clinics. Each patient will have adherence monitored using the Wisepill® electronic adherence monitoring device (EAM). After eligibility has been confirmed, each participant will be randomized to one of 16 experimental conditions. Each condition includes a unique combination of five adherence intervention components. Three of these components focus on identifying individuals with poor adherence, with increasing degrees of sophistication, with immediate linkage to adherence support. Two components focus on supporting good adherence. They both supplement the existing adherence support program delivered at the study clinics operated by City of Cape Town (standard of care component). Based on Self-Determination Theory, the investigators postulate these intervention components will: 1) enhance feelings of autonomy support, social support, and knowledge; 2) improve motivation and self-competence; and 3) increase ART retention, adherence, and viral suppression. A subset of the participants, as well as clinic staff, will be invited to in-depth interviews to explore mediating factors (Aim 1) and the implementation process (Aim 2); and the data collected in Aims 1 and 2 will be used to explore cost effectiveness (Aim 3).
Detailed description
The study's primary research goal is to identify the optimal combination of evidence-based and scalable HIV interventions for low-resource, high-burden settings. The investigators propose to 1) test the relative contribution of five promising intervention components; 2) collect cost and other implementation data; and 3) create a multi-component intervention package to optimize cost-effectiveness and implementation success. Of the five components, three are methods of non-adherence detection plus patient outreach; two are adherence support methods that can be integrated into Cape Town healthcare systems. These will not overcome all challenges that ART patients experience (e.g., structural barriers such as food insecurity) but they represent scalable, feasible, acceptable, and effective options. Notably, they are all behavioral approaches grounded in the experience and priorities of local health officials with whom the investigators have worked to identify scaleable interventions. While the study will be in Cape Town, it is broadly adaptable to other resource-limited settings.
The gold standard for testing interventions is the randomized controlled trial (RCT), which minimizes bias when testing cause and effect of a new exposure. When testing an intervention with more than one element, however, untangling the effect of individual elements is impossible. Indeed, data on the performance of individual components and their interactions-critical for developing and refining the components of a packaged intervention-is lost in an RCT. Notably, clinical care typically relies on packages of services, not single interventions, and packaged interventions are recommended for ART support. An effective way to test a multi-component intervention is to use the novel Multiphase Optimization STrategy (MOST), an engineering-inspired method for identifying the most efficacious combination of components in a packaged intervention, thus allowing researchers to drop inactive or weakly-performing components and construct an optimized package based on effect, cost, and other features. Once the optimized multi-component intervention is chosen, an RCT or quasi-experiment can follow to determine whether the optimized package yields superior outcomes compared to existing standards. MOST encompasses three phases: 1) preparation; 2) optimization; and 3) evaluation, often in an RCT. In this project, we have completed preparation, including a pilot study in Cape Town. SUSTAIN will comprise the middle optimization phase. The evaluation phase will be the focus of a future study.
The specific aims are:
Aim 1. Employ a highly efficient fractional factorial design to determine the effects of five intervention components on the primary outcome (HIV viral suppression) and secondary outcomes (ART adherence measured by EAM, ART retention per clinic records, days of unsuppressed virus, time to nonadherence detection, and time to linkage to support). The investigators will explore effect mechanisms quantitatively and qualitatively.
Aim 2. Evaluate the intervention components to address implementation, service, and client outcomes according to the Proctor framework. Data collection will involve tracking of intervention component use, time and motion studies, and quantitative surveys and qualitative interviews with participants and staff.
Aim 3. Use the effectiveness data collected in Aim 1 and the implementation and client outcomes in Aim 2 to model the multi-component intervention optimized for cost-effectiveness and implementation success.
Study Summary This study is designed to advance the translation of evidence-based interventions into clinical settings to benefit patients. There is ample evidence on what works to support ART adherence and retention-much of it from our own research. The investigators partnered with local officials and clinical staff in Cape Town to review the evidence and to conduct formative research to identify the most effective, acceptable, and feasible intervention options for patients and providers. The proposed study represents the next critical step: the investigators will test the intervention components that emerged from the formative work, encompassing elements to both rapidly identify nonadherent patients and to strengthen the support they receive once identified, to provide the data needed to construct the most cost-effective and sustainable multi-component intervention. The choice of intervention components will allow a critical test of advanced monitoring technology compared to simpler tools to identify nonadherence. By using an innovative MOST design to guide collection and analysis of efficacy, cost, and other implementation data, the study aligns with NIH's goals of using novel scientific methods to advance implementation science.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 16
- Model description
- The investigators will randomize subjects to one of 16 conditions, using a fractional factorial design to determine the effects of five intervention components.
| Arm | Type | Receives |
|---|---|---|
| Condition 1 | Experimental | Behavioral: S2/Peer: Enhanced peer group supportIncludes 1 intervention: S2/Peer: Enhanced peer group support. |
| Condition 2 | Experimental | Behavioral: S1/Text: Weekly check-in textsIncludes 1 intervention: S1/Text: Weekly check-in text messages. |
| Condition 3 | Experimental | Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed dosesIncludes 1 intervention: M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient. |
| Condition 4 | Experimental | Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S1/Text: Weekly check-in texts, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. |
| Condition 5 | Experimental | Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refillIncludes 1 intervention: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient. |
| Condition 6 | Experimental | Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: S1/Text: Weekly check-in texts, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. |
| Condition 7 | Experimental | Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support. |
| Condition 8 | Experimental | Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S1/Text: Weekly check-in textsIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages. |
| Condition 9 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test resultIncludes 1 intervention: M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result. |
| Condition 10 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: S1/Text: Weekly check-in texts, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. |
| Condition 11 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support. |
| Condition 12 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S1/Text: Weekly check-in textsIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages. |
| Condition 13 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: S2/Peer: Enhanced peer group supportIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support. |
| Condition 14 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: S1/Text: Weekly check-in textsIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages. |
| Condition 15 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed dosesIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient. |
| Condition 16 | Experimental | Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill, Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses, Behavioral: S1/Text: Weekly check-in texts, Behavioral: S2/Peer: Enhanced peer group supportIncludes 5 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (15 listed)
- Adults (≥18 years) and adolescents 16-17 years.
- HIV-positive and attending a local City of Cape Town (COCT) clinic to commence ART.
- Able to provide full informed consent, with a written signature. For those who are illiterate, a witness will be present throughout the process and will sign the form, while the participant will add their right thumb print. For those who are aged 16-17 years, informed written assent will be obtained, and the adolescent must have a parent or guardian who can provide full informed consent (see **below for how parent/guardian is defined for this purpose).
- Access to a working cellphone and willingness to receive study-related messaging on that phone.
- Willingness to comply with study procedures, including providing regular updates of contact details /locator information, and use a EAM device for the duration of participation.
Key exclusion criteria (10 listed)
- Clinical conditions as assessed by the COCT clinic clinicians at first visit e.g. renal disease, which preclude the use of a single tablet regimen (with the exception of those on tuberculosis (TB) treatment who are required to take an extra dose of dolutegravir daily).
- Planning to leave Cape Town permanently within the next 24 months.
- Being perinatally infected with HIV. Being infected from birth typically means a set of experiences and complications at a young age that require unique and special attention.
- If an adolescent, taking their ART medication as a syrup, as they are required to use the electronic adherence monitor (Wisepill device), which is only suitable for tablets.
- Aim 1: IDIs with trial subjects.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| M1/OTR: Immediate outreach to subject due to unsuppressed viral load test resultAlso: M1/OTRStandard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the "Risk of Treatment Failure" (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1. | Behavioural | Condition 10, Condition 11, Condition 12, Condition 13, Condition 14, Condition 15, Condition 16, Condition 9 |
| M2/PRM: Immediate outreach to subject after a missed pharmacy refillAlso: M2/PRMThe subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2. | Behavioural | Condition 13, Condition 14, Condition 15, Condition 16, Condition 5, Condition 6, Condition 7, Condition 8 |
| M3/EAM: Immediate outreach to subject after EAM-identified missed dosesAlso: M3/EAMThe subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2. | Behavioural | Condition 11, Condition 12, Condition 15, Condition 16, Condition 3, Condition 4, Condition 7, Condition 8 |
| S1/Text: Weekly check-in textsAlso: S1/TextSubject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. "how are you?" with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent. | Behavioural | Condition 10, Condition 12, Condition 14, Condition 16, Condition 2, Condition 4, Condition 6, Condition 8 |
| S2/Peer: Enhanced peer group supportAlso: S2/PeerSubject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. "Enhanced" peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks. | Behavioural | Condition 1, Condition 10, Condition 11, Condition 13, Condition 16, Condition 4, Condition 6, Condition 7 |
Primary outcome
HIV viral suppression at 24 months
Time frame: 24 months
This outcome will measure the effect of the interventions on HIV viral suppression from enrollment to the end of study participation. HIV viral suppression will be defined as % plasma viral load (VL) <50 copies/mL (dichotomous).
6 secondary outcomes
HIV viral suppression at 12 months
Time frame: 12 months
Change in HIV viral load between baseline and 12 months
Time frame: baseline, 12 months
Change in HIV viral load between baseline and 24 months
Time frame: baseline, 24 months
Days of unsuppressed virus between baseline and 24 months
Time frame: baseline, 24 months
Achievement of ≥ 90% adherence in month 24
Time frame: month 24
Mean adherence from baseline through 24 months
Time frame: baseline through 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Derived from this study: PubMed 37147725Jennings L, West RL, Halim N, Kaiser JL, Gwadz M, MacLeod WB, Gifford AL, Haberer JE, Orrell C, Sabin LL. Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design. Trials. 2023 May 5;24(1):310. doi: 10.1186/s13063-023-07322-z.
- Individual participant dataSharing planned: No. We have not yet made a detailed plan, but tentatively, we will deposit de-identified IPD in a repository at Boston University (BU) School of Public Health and the Desmond Tutu Health Foundation that can be made available to other researchers once our planned analyses are complete.
Related trials for HIV Infections
Not yet recruitingPhase 1
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Enrolling by invitation
Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection
HIV Infections
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Enrolling by invitation
Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women
HIV, HIV - Human Immunodeficiency Virus
Not yet recruitingPhase 4
Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
HIV-1 Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lora Sabin, PhD, MA principal investigator
Boston University
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses in people with HIV Infections and Adherence, Medication, run by Boston University at 3 sites in South Africa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIV viral suppression at 24 months (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05040841, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.